These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25132750)

  • 21. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
    Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
    Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
    Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
    Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helicobacter pylori.
    Malfertheiner P; Selgrad M
    Curr Opin Gastroenterol; 2014 Nov; 30(6):589-95. PubMed ID: 25268839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
    Papastergiou V; Georgopoulos SD; Karatapanis S
    World J Gastroenterol; 2014 Aug; 20(29):9898-911. PubMed ID: 25110420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B; Wang J; Li J; Liu L; Chen Y
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new look at anti-Helicobacter pylori therapy.
    Chuah SK; Tsay FW; Hsu PI; Wu DC
    World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Helicobacter pylori treatment: Still a work in progress.
    Senatore FJ; Wilmot J; Birk JW
    Postgrad Med; 2016 Jan; 128(1):152-7. PubMed ID: 26490697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance.
    Heo J; Jeon SW
    World J Gastroenterol; 2014 May; 20(19):5654-9. PubMed ID: 24914324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
    Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
    Romano M; Gravina AG; Nardone G; Federico A; Dallio M; Martorano M; Mucherino C; Romiti A; Avallone L; Granata L; Priadko K; Compare D; Tuccillo C; Romito MR; Sgambato D; Miranda A; Romano L; Loguercio C; Bazzoli F; Zagari RM
    Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Helicobacter pylori infection: Where are we now?
    Liou JM; Wu MS; Lin JT
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1918-1926. PubMed ID: 27088632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
    Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.
    Kanizaj TF; Kunac N
    World J Gastroenterol; 2014 Jan; 20(3):699-705. PubMed ID: 24574743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
    Graham DY; Dore MP; Lu H
    Expert Rev Anti Infect Ther; 2018 Sep; 16(9):679-687. PubMed ID: 30102559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.